Fast Five Quiz: C3G Management

A. Brent Alper, Jr, MD, MPH


April 24, 2023

Currently, the only approved and available complement-targeting therapies are eculizumab and ravulizumab, both of which are monoclonal antibodies targeting C5. Eculizumab targets glomerular inflammation but has no effect on complement deposition.

Rituximab and cyclophosphamide are both nonspecific immunomodulatory therapies that have minimal benefit for most patients with C3G.

Prednisone, a corticosteroid, is often added to nonspecific immunosuppressive agents, especially mycophenolate mofetil, to augment their efficacy. In general, patients experience higher response rates with the addition of a corticosteroid to immunosuppressive therapy than with immunosuppressive agents or corticosteroids alone.

Antibiotics are used to control local symptoms and to prevent spread of infection in cases of acute infection associated glomerulonephritis.

Learn more about immunosuppressive therapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.